U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

    {{facet.count}}
    {{facet.count}}

Showing 157931 - 157940 of 167129 results

Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (RACEMIC)


Mazindol is an amphetamine-like medicine which was developed by Sandoz in 1967 and approved by FDA for the treatment of obesity and Duchenne muscular dystrophy under the names Sanorex and Mazanor. The exact mechanism of action is unknown, but possibly involves the stimulation of beta-adrenergic receptors and inhibition of monoamine reuptake. Both Sanorex and Mazanor were withdrawn from the market by reason other than safety. NLS Pharma now is developing mazindol for Attention Hyperactivity Disorder in adults (phase II).
Status:
US Previously Marketed
Source:
Strotope by Squibb
(1973)
Source URL:
First approved in 1973
Source:
Strotope by Squibb
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Strontium cation Sr-85 is a soft, silver-yellow, alkaline-earth metal, existing either in the elemental state or as the divalent ion. Strontium-85 is a radioactive isotope that has a half-life of 64.84 days and it has been used for photoscanning in 1960s. Strontium 85 is admirably suited for photoscanning since, in its decay by electron capture to stable rubidium 85, a single gamma photon of 0.51 Mev is emitted. The material has administered intravenously, 50 µc to adults and 20 µc to patients under twenty years of age. The estimated total body dose to a standard man is 0.325 rads and the bone dose is 2.28 rads
Status:
US Previously Marketed
Source:
FERROUS CITRATE FE 59 by MALLINCKRODT
(1973)
Source URL:
First approved in 1973

Class (Stereo):
CHEMICAL (ACHIRAL)


Ferrous citrate Fe 59 is indicated, by intravenous administration, to determine various parameters of the kinetics of iron metabolism, including plasma iron clearance, plasma iron turnover rate, and the utilization of iron in new red blood cells. The values of serum iron obtained from these studies provide diagnostic information in patients with anemias. Ferrous citrate Fe 59 is also useful to assess the role of the spleen in red blood cell production and destruction, and thus to help determine the advisability of splenectomy. Also, organ uptake measurements are used to measure the sites of red cell production (or lack thereof) in extramedullary erythropoiesis in myeloproliferative disorders. Iron from ferrous citrate is bound to plasma protein (transferrin) and carried to the blood-forming organs where it is utilized to form hemoglobin or is deposited in the reticuloendothelial cells of the liver and spleen. The amount of radioactive iron absorbed, transported, stored, utilized, and excreted can then be measured by the periodic collection of blood specimens and external counting.
Status:
US Previously Marketed
Source:
Strotope by Squibb
(1973)
Source URL:
First approved in 1973
Source:
Strotope by Squibb
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Strontium cation Sr-85 is a soft, silver-yellow, alkaline-earth metal, existing either in the elemental state or as the divalent ion. Strontium-85 is a radioactive isotope that has a half-life of 64.84 days and it has been used for photoscanning in 1960s. Strontium 85 is admirably suited for photoscanning since, in its decay by electron capture to stable rubidium 85, a single gamma photon of 0.51 Mev is emitted. The material has administered intravenously, 50 µc to adults and 20 µc to patients under twenty years of age. The estimated total body dose to a standard man is 0.325 rads and the bone dose is 2.28 rads
Status:
US Previously Marketed
Source:
PROSTIN F2 ALPHA by PHARMACIA AND UPJOHN
(1973)
Source URL:
First approved in 1973
Source:
PROSTIN F2 ALPHA by PHARMACIA AND UPJOHN
Source URL:

Class (Stereo):
CHEMICAL (ABSOLUTE)



Dinoprost is the synthetic or partially synthetic, naturally-occurring prostaglandin F2 alpha (trade mark Prostin F2 alpha). Dinoprost has been used for therapeutic termination of pregnancy. Although the exact mode of action in pregnancy termination in humans is not fully defined, when Prostin F2 alpha is administered by the intrauterine route it initiates rhythmical uterine contractions which, if continued for a sufficient time, are capable of expelling the contents of the uterus. Sensitivity of the pregnant uterus to prostaglandins is lower during early and mid-pregnancy than at term.
Status:
US Previously Marketed
Source:
Voranil by U.S. Vitamin (USV)
(1973)
Source URL:
First approved in 1973
Source:
Voranil by U.S. Vitamin (USV)
Source URL:

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Clortermine hydrochloride (Voranil) is a non-amphetamine anorexigenic agent. Voranil, a sympathomimetic amine, is indicated for short-term adjunctive treatment of exogenous obesity. Its long duration of action permits once-a-day dosage. In a large number of patients studied, Voranil was found to be superior to placebo in weight reduction. Insomnia, dry mouth, palpitations and tachycardia have been reported in a small percentage of patients taking the drug. Voranil was originally developed by Ciba Pharmaceuticals Corporation and transferred to USV Pharmaceuticals Corporation in December 1971, as a result of a product exchange agreement.
Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Metrizoic acid is a diagnostic radiopaque that usually occurs as the sodium salt. The mechanism of action of metrizoic acid is as a X-Ray Contrast Activity.
Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Metrizoic acid is a diagnostic radiopaque that usually occurs as the sodium salt. The mechanism of action of metrizoic acid is as a X-Ray Contrast Activity.
Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (ACHIRAL)

Conditions:

Metrizoic acid is a diagnostic radiopaque that usually occurs as the sodium salt. The mechanism of action of metrizoic acid is as a X-Ray Contrast Activity.
Status:
US Previously Marketed
First approved in 1973

Class (Stereo):
CHEMICAL (ABSOLUTE)

Conditions:

Metrizoic acid is a diagnostic radiopaque that usually occurs as the sodium salt. The mechanism of action of metrizoic acid is as a X-Ray Contrast Activity.

Showing 157931 - 157940 of 167129 results